Montserrat Andrade Detrell
Director/Board Member chez PHARMA MAR, S.A.
Fortune : 30 M $ au 31/03/2024
Profil
Montserrat Andrade Detrell is currently the Director at Pharma Mar SA and a Member at Sociedad Española de Senología y Patología Mamaria.
Previously, she worked as the Head-Institutional Relations at Zeltia SA from 2007 to 2012.
Dr. Andrade Detrell has an undergraduate degree from Universidad Complutense de Madrid, a doctorate degree from Universidad Complutense de Madrid, a graduate degree from the University of Strasbourg, a doctorate degree from University Carlos III of Madrid, and a graduate degree from the University of Barcelona.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PHARMA MAR SA
5,14% | 13/06/2023 | 954 460 ( 5,14% ) | 30 M $ | 31/03/2024 |
Postes actifs de Montserrat Andrade Detrell
| Sociétés | Poste | Début |
|---|---|---|
| PHARMA MAR, S.A. | Director/Board Member | - |
| Sociedad Española de Senología y Patología Mamaria | Corporate Officer/Principal | - |
Anciens postes connus de Montserrat Andrade Detrell
| Sociétés | Poste | Fin |
|---|---|---|
| ZELTIA SA | Corporate Officer/Principal | 01/01/2012 |
Formation de Montserrat Andrade Detrell
| Universidad Complutense de Madrid | Undergraduate Degree |
| University of Barcelona | Graduate Degree |
| University of Strasbourg | Graduate Degree |
| University Carlos III of Madrid | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PHARMA MAR, S.A. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Zeltia SA
 Zeltia SA BiotechnologyHealth Technology Zeltia SA is a holding company, which develops marine-based drugs in the field of oncology. It operates through the Biopharmaceuticals and Consumer Chemicals segments. The Biopharmaceuticals segment engages in the research and marketing of anti-tumor drugs, diagnosis kits, and development of therapies based on reducing or silencing gene expression. The Consumer Chemicals segment produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and related products. The company was founded on August 3, 1939 and is headquartered in Madrid, Spain. | Health Technology |
| Sociedad Española de Senología y Patología Mamaria |
